Skip to content

Pasadena Star News

64°F
Friday, May 1st 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

9.075 -0.395 (-4.17%)
Delayed Quote Updated: 11:01 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Capricor Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Which stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
3 Small-Cap Biotechs With Binary Catalysts on the Calendar ↗
Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices. 
Via MarketBeat
News headline image
Activist Investor Sounds Alarm on Capricor’s Cash Burn ↗
Kaos Capital demands a governance reset and cash preservation at Capricor Therapeutics (NASDAQ: CAPR) as expenses rise. 
Via Benzinga
News headline image
Capricor (CAPR) Q2 2026 Earnings Call Transcript ↗
Deramiocel faces regulatory headwinds; management pursues upper limb indication. 
Via The Motley Fool
Topics Earnings
Capricor Therapeutics Inc (NASDAQ:CAPR) Q1 Results Show EPS Miss as Market Awaits August PDUFA Date ↗
Via Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Discover the top movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
Capricor Therapeutics Q2 Earnings Call Highlights ↗
Capricor Therapeutics (NASDAQ:CAPR) said its biologics license application for deramiocel remains under U.S. Food and Drug Administration review, while the company prepares to submit an amendment... 
Via MarketBeat
Topics Earnings
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved upwards... 
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Capricor Therapeutics Q2 2026 Earnings Call Transcript ↗
Capricor Therapeutics (NASDAQ:CAPR) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga... 
Via Benzinga
Topics Earnings
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Which stocks are moving on Monday? ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Monday. ↗
Via Chartmill
News headline image
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy? ↗
Focused on rare disease therapeutics, this biotech firm reported a notable insider sale amid a year of substantial stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy ↗
Capricor Therapeutics (NASDAQ:CAPR) executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its... 
Via MarketBeat
News headline image
Capricor (CAPR) Q1 2026 Earnings Transcript ↗
Capricor (CAPR) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Capricor Therapeutics Q1 Earnings Call Highlights ↗
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself... 
Via MarketBeat
Topics Earnings
News headline image
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story ↗
Focused on advanced cell therapies for rare diseases, this biotech firm reported a notable insider sale in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval ↗
On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval. 
Via Stocktwits
Topics Earnings
News headline image
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval ↗
The FDA has accepted Capricor’s resubmitted biologics license application, setting an Aug. 22 PDUFA decision date for Deramiocel in DMD. 
Via Stocktwits
Topics Earnings
News headline image
Capricor (CAPR) Q4 2025 Earnings Call Transcript ↗
Capricor (CAPR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.